GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Regeneron Pharmaceuticals, Inc. (REGN) [hlAlert]

Rating:
Buy REGN
up 63.97 %

Regeneron Pharmaceuticals, Inc. (REGN) rated Buy with price target $390 by Citigroup

Posted on: Monday,  Mar 17, 2014  8:25 AM ET by Citigroup

Citigroup rated Buy Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on 03/17/2014, when the stock price was $328.09. Since
then, Regeneron Pharmaceuticals, Inc. has gained 63.98% as of 01/27/2016's recent price of $538.00.
If you would have followed this Citigroup's recommendation on REGN, you would have gained 63.97% of your investment in 681 days.

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic drugs for thetreatment of serious medical conditions. Regeneron's platform technologies include Targeted GenomicsTM, FunctionomicsTM, and Designer Protein TherapeuticsTM. Regeneron has drugs in clinical and preclinical development for the potential treatment of obesity, rheumatoid arthritis, cancer, allergies, asthma, amyotrophic lateral sclerosis, constipating conditions, ischemia, and other diseases and disorders. (PRESS RELEASE)

Citi Investment Research is a highly respected research unit and is comprised of 390 research analysts across 22 countries. Citi Investment Research covers 3,100 companies, representing 90 percent of the market capitalization of the major global indices, and provides macro and quantitative analysis of global markets and sector trends. Combined with Citi's exceptional sales and trading capabilities and Smith Barney's financial consultants, the core focus of the group is to help investing clients make informed decisions by providing value-added, independent, insightful analysis.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/17/2014 8:25 AM Buy
None
328.09 390.00
as of 10/17/2014
1 Week up  7.60 %
1 Month up  2.93 %
3 Months up  24.70 %
1 YTD up  12.66 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy